All News

MAS in sJIA - retrospective multicenter study 147 pts- 2 peds clinics in Turkey. 22% developed MAS median 5 month multiple attacks per pt - highest being 4 51% remined on the same biologic and resulted in improvement @RheumNow #ACR21 #ACRBest #abst0246

Bella Mehta bella_mehta ( View Tweet)

Assisted reproductive tech for pts w/ rheum dz is safe for stable/quiescent dz #acr21 ⁦@ACRheum⁩ reproductive guideline ⁦@RheumNow⁩ https://t.co/312EuRSJrB
TheDaoIndex KDAO2011 ( View Tweet)

Fautrel reports mixed response to JAK Inhib. in 8 refractory Adult (6) & juvenile (2)-Onset Still's Dz w/ dz Dz duration 86 mos (7 Systemic, 1 Chr articular) w/ JAKi (Bari 4, Upa1, Tofa 2, Ruxo 2). There were no remissions, 50% had partial response @ 11 mos #ACR21 Abstr#0195 https://t.co/Ww8ONBrRqq

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

#ACR21 #pedsrheum With so much work ahead, what to tackle first? 1⃣Gathering and organizing the top 10 priorities in cSLE https://t.co/H3ASXAfM4m
Dr. Laura Lewandowski LauraLewMad11 ( View Tweet)
Rheum Radiology Bootcamp Rheum dz = increased risk of lung cancer Important note: Fleischner recs for incidental nodules do not apply to immunosuppressed patients. Stay on alert for malignancy. #ACR2021

Pedro Castillo _Castillo_Pedro ( View Tweet)

Consider baseline risk of lung cancer. Scleroderma and RA in particular at increased risk => lower threshold for getting initial CT. For incidental nodule, consider rescreening at 6-12 months, then space out. #ACR2021

Pedro Castillo _Castillo_Pedro ( View Tweet)

Brepocitinib (TYK2/JAK1i) superior to PBO in PsA at week 16, w/ improvements in refractory domains continuing over 52 weeks. There were more AEs in the brepocitinib groups vs PBO over 16 weeks. Abs 0488 #ACR21 #RheumNow @RheumNow https://t.co/umk4REJwkS https://t.co/JYZVR3jyY5

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
BE AGILE: No new safety signals in AS pts treated with BKZ ( IL-17F/IL-17Ai) and remains efficacious as a potential treatment in AS. Abs 0491 #ACR21 #RheumNow @RheumNow https://t.co/fGT8n5Hx9C https://t.co/rjPTla7JId

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Common sense to ⬇️#rheumatoidarthritis 6S412 G Burmester summarizes decades of RA research - avoidance strategies =healthy lifestyle. ?asked is sero+RA diff than seronegative? Maybe. other Abs likely exist @RheumNow #ACR21 #ACRBest https://t.co/RT3dHDfdWp
Janet Pope Janetbirdope ( View Tweet)
After elegantly laying out the sophisticated science at #ACR21, Gerd Burmester finishes with this: Without waiting, 11 things we can actually do now to reduce our chance of RA @The_IMJ Ranjeny Thomas and @lynmarch1 et al @RheumNow https://t.co/Be1Jyw9FOo
David Liew drdavidliew ( View Tweet)
I'm wearing my badge, just in case... #RheumPix https://t.co/UvgCinq8Bn
Dr. John Cush RheumNow ( View Tweet)
Spinal involvement: fine, symmetric syndesmophytes (axSpA) vs bulky, asymmetric syndesmophytes (axPsA) #ACR21 https://t.co/7leGTjm4fb
Rheum Cat rheum_cat ( View Tweet)
@AUGarren @DavidLeverenz demonstrate significant gaps in DMARD lab safety monitoring in telehealth setting. Small improvement over time but still <50% 😱 Abstr#0146 #ACR21 @RheumNow https://t.co/FDp7ZwzfO5
Richard Conway RichardPAConway ( View Tweet)
Deucravacitinib (TYK2 inhibitor) for PsA tx showed biomarker changes consistent with clinical improvement ⬇️IL-23, IL-17 and IFN-1 pathways vs. pbo ⬇️MMP3 (associated with joint damage), C4M Abs#490 #ACR21 @RheumNow https://t.co/mA1aHmtE5I https://t.co/BoAPKiMW9x

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
Skin Findings in Patients of Color with Rheumatic Disease #ACR21. Don't miss lupus panniculitis. https://t.co/kM6XbFtNoW
Sali Merjanah SMerjanah ( View Tweet)
Brepocitinib (TYK2/JAK1 inhibitor) phase 2b study for PsA treatment ⬆️ACR20, 50, 70 response vs. pbo ⬆️secondary outcomes vs. pbo ⬆️serious AE vs. pbo, ⬆️zoster ⭐️no MACE/VTE/death reported Abs#488 #ACR21 @RheumNow https://t.co/KdAHQGjTMZ https://t.co/ugk3rkxX9t

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
OK am trying to learn about VEXAS ⬇️hearing, periorbital Edelman, chondritis, VTE, pulmonary infiltrates, Sweets, Arthritis. Genetic adult auto inflammatory syndrome ⬆️Men Rx steroids, then IL6i, etc. IL1i has ⬆️skin reactions 6S410 #ACR21 #gamechanger @RheumNow #ClinicalPearl https://t.co/OYRi1yAal5
Janet Pope Janetbirdope ( View Tweet)
Too many great points in this presentation! Making sense of the IL-23 inhibitor failure in axSpA studies. From Dr. Atul Deodhar's presentation at #ACR21 6S403 session @RheumNow https://t.co/Iv0LCNob5J
Pedro Castillo _Castillo_Pedro ( View Tweet)
Abst 0482 Baker and colleagues showed that in patients with Type 2 DM, metformin use is associated with significantly lower risk of developing #OA and time to joint replacement #ACR21 @RheumNow https://t.co/a00g3HMrM0
Akhil Sood MD AkhilSoodMD ( View Tweet)
×